Cadinha Co buys $11,651,393 stake in Eli Lilly and Co (LLY)

Eli Lilly and Co (LLY) : Cadinha Co scooped up 121,646 additional shares in Eli Lilly and Co during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 8, 2016. The investment management firm now holds a total of 144,630 shares of Eli Lilly and Co which is valued at $11,651,393.Eli Lilly and Co makes up approximately 2.41% of Cadinha Co’s portfolio.

Other Hedge Funds, Including , Twin Capital Management Inc reduced its stake in LLY by selling 1,300 shares or 3.83% in the most recent quarter. The Hedge Fund company now holds 32,640 shares of LLY which is valued at $2,629,478. Eli Lilly and Co makes up approx 0.19% of Twin Capital Management Inc’s portfolio. Concannon Wealth Management added LLY to its portfolio by purchasing 200 company shares during the most recent quarter which is valued at $16,544. Eli Lilly and Co makes up approx 0.02% of Concannon Wealth Management’s portfolio.Douglas Lane Associates reduced its stake in LLY by selling 153 shares or 2.0% in the most recent quarter. The Hedge Fund company now holds 7,479 shares of LLY which is valued at $623,749. Eli Lilly and Co makes up approx 0.02% of Douglas Lane Associates’s portfolio.Security National Trust Co boosted its stake in LLY in the latest quarter, The investment management firm added 290 additional shares and now holds a total of 13,950 shares of Eli Lilly and Co which is valued at $1,138,181. Eli Lilly and Co makes up approx 0.41% of Security National Trust Co’s portfolio. Svenska Handelsbanken Ab (publ) added LLY to its portfolio by purchasing 731,499 company shares during the most recent quarter which is valued at $58,051,761. Eli Lilly and Co makes up approx 3.47% of Svenska Handelsbanken Ab (publ)’s portfolio.

Eli Lilly and Co opened for trading at $80.33 and hit $80.62 on the upside on Monday, eventually ending the session at $80.26, with a gain of 0.05% or 0.04 points. The heightened volatility saw the trading volume jump to 27,80,381 shares. Company has a market cap of $88,594 M.

On the company’s financial health, Eli Lilly and Co reported $0.86 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jul 26, 2016. Analyst had a consensus of $0.85. The company had revenue of $5404.80 million for the quarter, compared to analysts expectations of $5157.09 million. The company’s revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.90 EPS.

Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers develops manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company’s products are sold in approximately 120 countries. The Company’s human pharmaceutical business segment sells medicines which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division which develops manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States Puerto Rico and 11 other countries. Its products include endocrinology products neuroscience products oncology products cardiovascular products products for food animals products for companion animals and Novartis AH products.

Leave a Reply

Eli Lilly and Co - Is it time to Sell?

Top Brokerage Firms are advising their investors on Eli Lilly and Co. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.